1 Polio Eradication Program in India: Actions in Post-Eradication Phase By Prasanta K. SahaPrasanta K. Saha, M.Sc., FRSS(UK), CSTAT(UK) Sr. Consultant:

Slides:



Advertisements
Similar presentations
WorkSafe Victoria is a division of the Victorian WorkCover Authority Guidance Note on the Prevention of Bullying and Violence at Work Evaluation results.
Advertisements

Module 1 Introduction to the polio endgame rationale and IPV vaccine
Polio Eradication Dr Marvin Hsiao Division of Medical Virology NHLS/UCT/Groote Schuur Hospital.
IPV IPV Rapidly produces high level of protective antibodies No risk of vaccine associated illness No interference from other enteroviruses. I.P.V. produces.
بسم الله الرحمن الرحيم. IRAN Vaccination policy for post eradication phase Presented by : A. R.ESTEGHAMATI, MD IRAN EPI Manager.
Role of the laboratory in disease surveillance
Accident/Incident Investigation
POLIO ERADICATION PROGRAM IN INDIA BY P. K. SAHA , M
Global Action Plan for Laboratory Containment of Wild Polioviruses
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
What Is It And How Will We Measure It?
Supporting Routine AND Supplementary Immunization Activities in STOP.
WHO RAP Team: Perspective and Update WORKSHOP ON ANALYZING THE POLIO ERADICATION ENDGAME, Seattle, 1-2 July 2015.
Completing The Endgame Global Polio Eradication
Polio eradication programme in India – Progress, Response and Issues for action Dr Ajay Khera Deputy Commissioner Ministry of Health & FW, Govt. of India.
The Evolving 'Polio Endgame' Strategy
PANDEMIC RISK. 3 pre-requisites for a Pandemic 1. The emergence of a new virus strain with no circulating immunity within the human population 2. The.
Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division.
Update on activities under laboratory containment of wild Polio viruses in India Dr. Rashmi Arora Scientist G & Head Division of Epidemiology & Communicable.
Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.
DPG HEALTH MEETING USAID CONFERENCE ROOM 6 NOVEMBER 2013 International Health Regulation (2005)
Inter-Departmental Working Group
Polio End-game: What are the implications on polio vaccination policy? Dr Raju Shah.
The Challenge: How to Accelerate Eradication and the 'Endgame'?
Adverse Events following Immunization (AEFI) Monitoring and Causality Assessment An Overview Department of Disease Control Ministry of Public Health Bureau.
National Certification Committee for Polio Eradication Proposed Work Plan Till th IEAG Meeting, New Delhi, March, 2012.
Introduction of Hib in UIP Dr. Prashant P. Ghodam Moderator : Dr. Ranjan Solanki.
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
NVAC W. R. Dowdle. Laboratory Containment of Wild Poliovirus in the United States Phase I National Survey and Inventory Final Report January.
Safety organization and training. The biosafety officer and biosafety committee A safety policy, A safety manual, and Supporting programmes for their.
January 2005 Polio Eradication Initiative NVAC Meeting February Polio Eradication: Global Progress and Post-Eradication Strategies.
1 Progress Towards Polio Eradication in EMR. 2 Status of global eradication Priority countries (except EMR) : Intensification : Certification,
Health Service Delivery Cluster Response to Typhoon Yolanda Center for Health Development- Western Visayas.
Progress of Polio Eradication in India, Current Risks & Actions taken on last IEAG report 24 th IEAG, New Delhi 15 March 2012 Dr. Ajay Khera Deputy Commissioner.
Polio Eradication and End Game Strategy
JAHSR TECHNICAL REVIEW MEETING EPI Report Dr Dafrossa C Lyimo Programme Manager 7th September 2010 Dar es salaam.
Measles elimination Dr. As’ad Ramlawi Palestine..
Vaccine-Derived Poliovirus Infections in an Amish Population Minnesota, 2005 Harry F. Hull, M.D. State Epidemiologist Minnesota Department of Health.
Sustaining Polio Eradication IEAG March 2012 The experience of polio-free countries with importations of WPV: Implications for India.
Polio Eradication -- Global Progress and Development of Post-Eradication Strategies: Implications for U.S. Stockpile and Outbreak Response Preparations.
TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.
1 |1 | Situation Update Influenza A (H1N1), 26 May 09.
Polio Endgame Strategy in India Considerations and Way Forward WHO-India, NPSP 15 March 2012.
1 Polio Strategic Plan India Expert Advisory Group July 2011 Impact & prospects at the half-way point.
Global Polio Eradication Initiative The 'Intensified Effort' 18 May 2008.
ASDPE International Health Regulations (IHR 2005) Laboratory and Zoonosis update Dr Richard Brown, WHO Thailand Workshop on Laboratory Diagnosis for Zoonotic.
Poliovirus Surveillance and Risks to Polio Eradication in India Dr. Hamid Jafari WHO-NPSP.
NVAC The Global Certification Commission declares the world polio-free when: No wild poliovirus has been found for at least 3 consecutive years.
National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization.
Poliovirus Surveillance status of quality, actions to improve sensitivity WHO-India 15 March 2012.
February 2015 An introduction to the switch from trivalent to bivalent oral polio vaccines 1.
1 Polio Eradication & Post Eradication Vaccination Policy March 2007.
Module 1 Introduction to the polio endgame rationale and IPV vaccine
Polio and Polio Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention.
Best wishes from B.P.Koirala Institute of Health Sciences Dharan, Nepal Dr. Nilambar Jha, MBBS, MD, Diploma in Health system Management (Israel) Professor.
Perspective and Update
Introduction to the polio endgame rationale and IPV vaccine
Vaccine-Derived Poliovirus Outbreak Minnesota, 2005
The next phase of polio eradication and the vaccines used
The Polio Eradication and Endgame Strategic Plan
World Health Organization
Communicating with caregivers about IPV and multiple injections
المرحلة القادمة من القضاء على شلل الأطفال واللقاحات المستخدمة
World Health Organization
Independent Monitoring of the Switch
The next phase of polio eradication and the vaccines used
Preparing for the Switch
Training for rotavirus vaccine introduction
Training for rotavirus vaccine introduction
The next phase of polio eradication and the vaccines used
Presentation transcript:

1 Polio Eradication Program in India: Actions in Post-Eradication Phase By Prasanta K. SahaPrasanta K. Saha, M.Sc., FRSS(UK), CSTAT(UK) Sr. Consultant: National Council of Applied Economic Research, India [Former Chief Director: Ministry of Health & Family Welfare, & Additional Director General: Ministry of Statistics & Program Implementation, Govt. of India] ,

2 Polio Eradication Program in India: Actions in Post-Eradication Phase Under the Polio Eradication program of India, the most relevant issues-both technical and administrative, which will arise in post-eradication situation, are discussed in this lecture.

3 Polio Eradication Program in India: Actions in Post-Eradication Phase That Polio Eradication program in India is extraordinarily time-overrun is well known. Original target was the year 2000-revised as 2002-further revised as Unfortunately the last revised target of the year 2005 could also not be achieved.

4 Contd. It is evident from the factual positions that the whole matter is bordering uncertainty. Polio Cases in India as on 5 th June, 2006: Total Polio Cases 2004: 134 Total Polio Cases 2005: 65 Total Polio Cases 2006(as on 5 th June,06): 36

5 Contd. Location of most recent cases: Uttar Pradesh (23), Bihar (12) & Madhya Pradesh (1) Though WHO designed global eradication strategy in1988, India participated much late in 1995.

6 Contd. Serious Actions needed in Post- Eradication Phase First to characterize the actual factors that country-level policy makers must weigh to manage polio risks during the first 5 years after certification by WHO.

7 Contd. Policy makers are to primarily formulate policies related to (a) routine and supplemental immunization, (b) outbreak response (including whether to create a stockpile), (c) surveillance and (d) containment of Wild & Vaccine-Derived Polio Viruses (VDPVs).

8 Contd. Global certification will occur once all 6 Regions of World Health Organization (WHO) confirm no wild poliovirus under high-quality surveillance for at least 3 years and the Global Certification Commission becomes satisfied that sufficient laboratory containment exists.

9 Contd. Determination of reasons for high incidence of vaccine failure Answer to this query is derived from some of the reasons as revealed in various PPI rounds are as follows:

10 Contd. Expiry of effectiveness of a few vials of vaccine. Portable cold storage containing the vaccines not providing desired cool temperature Note: A few vials of Polio vaccines might have expired their effectiveness but that might have escaped notice of the health workers. It has been experienced that in rural areas

11 Contd. the portable cold storage containing the vaccines does not provide desired cool temperature as the ice kept inside gets melted after sometime and there is no scope of filling it with fresh ice because the same is not available in the locality [NPSU, WHO regional office, New Delhi may supplement with further information].

12 Contd. Even that great event of eradication of Polio takes place in India in near future, there are more serious concerns in the post -eradication phase which will need appropriate attention and actions. Those technical problems are narrated below:

13 Contd. As eradication process approaches finishing line, there is greater need for new polio vaccines. These new vaccines will be needed to create a stockpile for future outbreaks.

14 Contd. Experts may be aware: (1) After eradication there was again outbreak of Polio in China [ after 5 years], Hispaniola [after 6 years], the Philippines [ after 4 years], Madagascar [ after 3 years] and in Egypt [ perhaps, after 25 years].

15 Contd. (2) Effective bio-containment of all existing polio viruses is essential to minimize risk of accidental infections. Such arrangement is yet to be initiated in India.

16 Contd. OPV Cessation Plan: As concerned experts dealing with eradication program may be aware, after eradication, use of OPV [Oral Polio Vaccine] should be discontinued to minimize the possibility of mutated strains of vaccines leading to new out-breaks.

17 Contd. WHO has discovered that out-break in China was caused by Circulating Vaccine Derived Polio Virus (cVDPV) mutated from OPV. Normally after eradication, manufacturing of trivalent OPV gets stopped.

18 Contd. This plan will take into account the risk of reintroducing virulent poliovirus from a laboratory or a manufacturing unit.

19 Contd. So there is need of manufacturing mono-valent OPV [mOPV] ( WHO, perhaps, has granted license to some Indian company). A proper strategy is to be formulated to guarantee that Polio outbreak does not recur.

20 Contd. Recent discussions predominantly focused on stopping immunization as the ultimate goal of the eradication initiative and on characterizing related issues.

21 Contd. Policy Options for the First 5 Years Following Certification: From the analysis of the implications of delays in outbreak response, experts recommended: (a) maintaining active surveillance for at least 5 years after ceasing all polio vaccination, (b) minimizing delays in diagnosis and confirmation of an outbreak,

22 Contd. (c) restricting poliovirus work to a few high-level containment laboratories, (d) maintaining OPV manufacturing capacity, and (e) establishing a stockpile and a response protocol for outbreaks.

23 Contd. Routine Immunization Current policies: The decision to vaccinate routinely requires choosing both the type of vaccine for use and the schedule for vaccine administration. Currently, the WHO recommends that each child receive 4 doses of trivalent oral polio vaccine [tOPV]

24 Contd. (administered at 6, 10, and 14 weeks, with the fourth dose given either at birth or within the first year) in order to be fully protected against polio. Consistent with this recommendation, most countries perform primary vaccination (defined as the first 3 doses of polio vaccination) with tOPV.

25 Contd. Post-certification options: In the post-certification era, routine immunization policies include stopping vaccination altogether, using the same or a different vaccine, and changing or maintaining the vaccination schedule.

26 Containment Strategies Current policies: Containment strategies focus on reducing the risk of reintroduction of poliovirus into the environment, notably through vaccine manufacturing facilities and laboratories that handle materials that could contain poliovirus (wild or vaccine-related).

27 Contd. WHO recommends that laboratories handle wild poliovirus infectious or potentially infectious materials under biosafety level procedures. According to guidance of WHO policy, countries are required to complete a national inventory of wild poliovirus infectious materials and potentially wild poliovirus infectious materials before global certification of eradication.

28 Contd. Management of Chronic Excretors of Polioviruses Current policies: No known cases exist of chronic excretion of wild poliovirus. WHO reports have catalogued a cumulative experience consisting of a total of 19 immuno- deficient chronic excretors of vaccine-derived polioviruses (iVDPV) globally in more than 40 years of OPV use. These individuals lived in middle level to upper-level income countries, primarily in the United States and Europe.

29 Contd. Management of Chronic Excretors of Polioviruses: Current policies-continued Assessment of the sensitivity of the AFP surveillance system for detecting iVDPV is needed, given that prolonged excretion may occur prior to the development of paralysis. To manage the risk of reintroduction of poliovirus to the community from identified patients, countries may choose whether to conduct screening and/or offer education about strategies for minimizing exposure to others.

30 Contd. Acknowledgement: 1. ‘Nature’,Vol.434,April,2005: ‘ A global call for new polio vaccines’ 2. Dr. François Bompart, Aventis Pasteur, 2, avenue Pont Pasteur, Lyon Cedex 07, France. 3. Nalinee Sangrujee, PhD, MPH; Radboud J. Duintjer Tebbens, MS; and others: Medscape General Medicine: ‘Policy Decision Options During the First 5 Years Following Certification of Polio Eradication’.

31 PEP in India: Actions in Post-Eradication Phase THANKS For any query I may me contacted through my s: